Your browser doesn't support javascript.
loading
Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies.
Chan, Anissa S H; Kangas, Takashi O; Qiu, Xiaohong; Uhlik, Mark T; Fulton, Ross B; Ottoson, Nadine R; Gorden, Keith B; Yokoyama, Yumi; Danielson, Michael E; Jevne, Trinda M; Michel, Kyle S; Graff, Jeremy R; Bose, Nandita.
Afiliação
  • Chan ASH; HiberCell Inc., Roseville, MN, United States.
  • Kangas TO; Biothera Pharmaceuticals Inc., Eagan, MN, United States.
  • Qiu X; HiberCell Inc., Roseville, MN, United States.
  • Uhlik MT; Biothera Pharmaceuticals Inc., Eagan, MN, United States.
  • Fulton RB; HiberCell Inc., Roseville, MN, United States.
  • Ottoson NR; Biothera Pharmaceuticals Inc., Eagan, MN, United States.
  • Gorden KB; Biothera Pharmaceuticals Inc., Eagan, MN, United States.
  • Yokoyama Y; Biothera Pharmaceuticals Inc., Eagan, MN, United States.
  • Danielson ME; Biothera Pharmaceuticals Inc., Eagan, MN, United States.
  • Jevne TM; Biothera Pharmaceuticals Inc., Eagan, MN, United States.
  • Michel KS; Biothera Pharmaceuticals Inc., Eagan, MN, United States.
  • Graff JR; HiberCell Inc., Roseville, MN, United States.
  • Bose N; Biothera Pharmaceuticals Inc., Eagan, MN, United States.
Front Oncol ; 12: 869078, 2022.
Article em En | MEDLINE | ID: mdl-35692755

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article